Company Description

ImmunoMet Therapeutics, a HanAll Biopharma company, is a clinical stage biotechnology company targeting metabolism for the treatment of selected cancers and fibrotic diseases. ImmunoMet’s lead molecule, Lixumistat, is the first PC1 inhibitor to complete Phase 1 with good tolerability.